Stoke Therapeutics and Biogen have begun dosing in the global Phase III EMPEROR study of zorevunersen for Dravet syndrome, ...

The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...

Cambridge, Massachusetts Wednesday, August 13, 2025, 15:00 Hrs [IST] ...

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Reports Q2 revenue $13.8M, consensus $5.2M. “This quarter was defined by strong execution that is driving momentum across our business,” said Ian ...

Stoke Therapeutics ( ($STOK) ) has released its Q2 earnings. Here is a breakdown of the information Stoke Therapeutics presented to its investors.

Analysts have given Stoke Therapeutics a total of 3 ratings, with the consensus rating being Buy. The average one-year price target is $29.0, indicating a potential 121.37% upside.

In the EMPEROR trial, children with a confirmed variant in the SCN1A gene not associated with gain-of-function mutations will receive zorevunersen or a placebo.

CW Petroleum Corp (OTCQB: CWPE) (the 'Company” or 'CWPE”), a leading provider of Specialty Renewable and Hydrocarbon Motor ...

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its ...